ReviewActa pharmacologica Sinica2016
Advances in development of fluorescent probes for detecting amyloid-β aggregates.
Review in Acta pharmacologica Sinica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 93 citations in OpenAlex.
- Recent Advances in Organofluoroprobes for Brain Imaging: Progress, Challenges, and Future Directions.ACS pharmacology & translational science · 2026Review
- Fluorescence spectroscopy and machine learning methods for detection of Alzheimer's disease from circulating white blood cells.Journal of Alzheimer's disease : JAD · 2026Article
- Amyloid-beta induces distinct forms of cell death in different neuronal populations.Cell death and differentiation · 2026Article
- Unveiling the Light Induced Energy Transfer Events in Water Soluble Benzothiazole Appended Borondipyrromethene: Synthesis, Photophysical Study, and Applications to Amyloid Binding.Chemistry, an Asian journal · 2026Article
- Curcumin as theranostics: imaging-guided therapeutics in oncology and neurodegenerative diseases.Frontiers in nutrition · 2026Review
- A ratio electrochemiluminescence sensor for monitoring amyloid-beta based on g-CMikrochimica acta · 2025Article
- Ligands for Protein Fibrils of Amyloid-β, α-Synuclein, and Tau.Chemical reviews · 2025Review
- Experimental methods for studying amyloid cross-interactions.Protein science : a publication of the Protein Society · 2025Review
- Recent Advancements in Biosensors for the Detection and Characterization of Amyloids: A Review.The protein journal · 2024Review
- Adding intrinsically disordered proteins to biological ageing clocks.Nature cell biology · 2024Review
- Medicinal (Radio) Chemistry: Building Radiopharmaceuticals for the Future.Current medicinal chemistry · 2024Review
- Two-Photon Fluorescent Probes for Amyloid-β Plaques Imaging In Vivo.Molecules (Basel, Switzerland) · 2023Review
- Discovery of High-Affinity Amyloid Ligands Using a Ligand-Based Virtual Screening Pipeline.Journal of the American Chemical Society · 2023Article
- A review of the current research on in vivo and in vitro detection for alpha-synuclein: a biomarker of Parkinson's disease.Analytical and bioanalytical chemistry · 2023Review
- Practical Guidance for Developing Small-Molecule Optical Probes for In Vivo Imaging.Molecular imaging and biology · 2023Review
- Neuroimaging modalities in the detection of Alzheimer's disease-associated biomarkers.Psychoradiology · 2023Review
- Exploring the Effect of Aliphatic Substituents on Aryl Cyano Amides on Enhancement of Fluorescence upon Binding to Amyloid-β Aggregates.ACS chemical neuroscience · 2021Article
- Amphiphilic Distyrylbenzene Derivatives as Potential Therapeutic and Imaging Agents for Soluble and Insoluble Amyloid β Aggregates in Alzheimer's Disease.Journal of the American Chemical Society · 2021Article
- Neutrophil Granule Proteins Inhibit Amyloid Beta Aggregation and Neurotoxicity.Current Alzheimer research · 2021Article
- Identification of Multicolor Fluorescent Probes for Heterogeneous Aβ Deposits in Alzheimer's Disease.Frontiers in aging neuroscience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With accumulating evidence suggesting that amyloid-β (Aβ) deposition is a good diagnostic biomarker for Alzheimer's disease (AD), the discovery of active Aβ probes has become an active area of research. Among the existing imaging methods, optical imaging targeting Aβ aggregates (fibrils or oligomers), especially using near-infrared (NIR) fluorescent probes, is increasingly recognized as a promising approach for the early diagnosis of AD due to its real time detection, low cost, lack of radioactive exposure and high-resolution. In the past decade, a variety of fluorescent probes have been developed and tested for efficiency in vitro, and several probes have shown efficacy in AD transgenic mice. This review classifies these representative probes based on their chemical structures and functional modes (dominant solvent-dependent mode and a novel solvent-independent mode). Moreover, the pharmaceutical characteristics of these representative probes are summarized and discussed. This review provides important perspectives for the future development of novel NIR Aβ diagnostic probes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.